➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Express Scripts
AstraZeneca
Harvard Business School
Dow

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NALTREXONE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Naltrexone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000195 ↗ Neurobiology of Opioid Dependence: 4 - 4 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 1993-01-01 The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.
NCT00000195 ↗ Neurobiology of Opioid Dependence: 4 - 4 Withdrawn Yale University Phase 2 1993-01-01 The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.
NCT00000196 ↗ Neurobiology of Opioid Dependence: 5 - 5 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 1993-01-01 The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.
NCT00000196 ↗ Neurobiology of Opioid Dependence: 5 - 5 Withdrawn Yale University Phase 2 1993-01-01 The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.
NCT00000230 ↗ Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-01-01 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.
NCT00000230 ↗ Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 Completed University of Vermont Phase 2 1995-01-01 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Naltrexone

Condition Name

Condition Name for Naltrexone
Intervention Trials
Alcoholism 54
Alcohol Dependence 49
Obesity 26
Opioid-Related Disorders 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Naltrexone
Intervention Trials
Alcoholism 110
Opioid-Related Disorders 49
Disease 44
Substance-Related Disorders 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Naltrexone

Trials by Country

Trials by Country for Naltrexone
Location Trials
United States 701
Canada 14
Germany 13
China 12
Russian Federation 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Naltrexone
Location Trials
New York 64
Connecticut 51
California 48
Pennsylvania 45
Texas 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Naltrexone

Clinical Trial Phase

Clinical Trial Phase for Naltrexone
Clinical Trial Phase Trials
Phase 4 95
Phase 3 60
Phase 2/Phase 3 32
[disabled in preview] 200
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Naltrexone
Clinical Trial Phase Trials
Completed 233
Not yet recruiting 81
Recruiting 63
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Naltrexone

Sponsor Name

Sponsor Name for Naltrexone
Sponsor Trials
National Institute on Drug Abuse (NIDA) 88
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 56
Yale University 36
[disabled in preview] 78
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Naltrexone
Sponsor Trials
Other 442
NIH 162
Industry 108
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Colorcon
Dow
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.